Prediction markets as research inputs

This points to prediction markets becoming a real research input, not just a side bet. For an investor tracking a biotech stock, an earnings setup, or a regulatory ruling, the market price on a yes or no contract can act like a live consensus forecast. That is useful when the stock bundles many moving parts together, but the event contract isolates one specific question.

• The workflow is concrete. A fund can look at a drug maker, check an FDA contract on Kalshi or Polymarket, read that price as an implied probability, then decide whether to buy the stock, trim it, or hedge elsewhere. Both venues now list biotech and FDA markets directly.
  1 sacra 4 kalshi 5 polymarket
• The reason to have a dedicated analyst is that these markets are fragmented and still immature. Kalshi and Polymarket use different market structures, and new infrastructure companies like Dome exist to normalize the same event across venues and route to the best price and liquidity.
  2 sacra 3 sacra 4 kalshi
• The limitation is liquidity. Prediction markets can express a tighter thesis than a stock trade, but volume is still concentrated in sports and a small set of power users. That makes them strongest today as signal and niche hedge, rather than as the primary place to size a large institutional position.
  2 sacra 3 sacra 4 kalshi

Over time, the edge shifts from simply noticing these markets to systematically combining them with company research, filings, and portfolio construction. The firms that win will treat prediction market prices as one more live data feed, then decide when to use that signal to inform a stock trade and when to trade the event itself.